Despite being a fintech company that was adversely affected by the COVID-19 pandemic where international travel restrictions stalled a sizable portion of international payment processing revenue, Novatti has weathered the pandemic by expanding other areas of the business which have enabled the Company to emerge in a stronger position than it was pre-pandemic.
Emerald Financial maintains its Buy rating on Novatti which re-allocated resources between its various business divisions to set a foundation for substantial revenue growth in FY21 and beyond through core tech partnerships.
Key Highlights:
…
This is only a brief excerpt of the report. To download it in full, simply register for free in the form provided.
*Owners of this website are NOV shareholders
**NOV has engaged Principal IR on retainer to assist with Investor Communications
Adelaide-based metal printing group books record $12.5 million revenue and a record $78 million sales…
Harris Technology has found a higher-margin growth engine in an unlikely place: the market for…
Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial…
Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market…
The race to secure Western-aligned critical minerals supply chains is accelerating as governments and industry…
Green360 Technologies (ASX:GT3) has taken a major step forward in the commercialisation of its low-carbon…